Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1995 Feb;33(2):481–483. doi: 10.1128/jcm.33.2.481-483.1995

Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates.

R Q Warren 1, M T Wong 1, G P Melcher 1, S P Blatt 1, P Cahn 1, H Perez 1, I Zapiola 1, M B Bouzas 1, G Muchinik 1, S A Anderson 1
PMCID: PMC227971  PMID: 7714212

Abstract

Utilizing peptides based on the V3 region of gp120, we undertook a serologic examination of human immunodeficiency virus type 1 (HIV-1)-infected individuals from Argentina to determine if prevalent HIV-1 isolates could be identified in this population. Our findings suggest that a similar pool of HIV-1 subgroup B isolates exists in both Argentina and the United States.

Full Text

The Full Text of this article is available as a PDF (145.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman P. W., Matthews T. J., Riddle L., Champe M., Hobbs M. R., Nakamura G. R., Mercer J., Eastman D. J., Lucas C., Langlois A. J. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol. 1992 Jul;66(7):4464–4469. doi: 10.1128/jvi.66.7.4464-4469.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gómez Carrillo M., Piccardo C., Libonatti O. Análisis molecular del principal epítope de neutralización ("V3 loop") del virus de la inmunodeficiencia humana tipo 1 de la Argentina. Rev Argent Microbiol. 1992 Apr-Jun;24(2):91–101. [PubMed] [Google Scholar]
  3. Haigwood N. L., Nara P. L., Brooks E., Van Nest G. A., Ott G., Higgins K. W., Dunlop N., Scandella C. J., Eichberg J. W., Steimer K. S. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol. 1992 Jan;66(1):172–182. doi: 10.1128/jvi.66.1.172-182.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Louwagie J., Delwart E. L., Mullins J. I., McCutchan F. E., Eddy G., Burke D. S. Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res Hum Retroviruses. 1994 May;10(5):561–567. doi: 10.1089/aid.1994.10.561. [DOI] [PubMed] [Google Scholar]
  5. Louwagie J., McCutchan F. E., Peeters M., Brennan T. P., Sanders-Buell E., Eddy G. A., van der Groen G., Fransen K., Gershy-Damet G. M., Deleys R. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 1993 Jun;7(6):769–780. doi: 10.1097/00002030-199306000-00003. [DOI] [PubMed] [Google Scholar]
  6. Nara P. L., Robey W. G., Pyle S. W., Hatch W. C., Dunlop N. M., Bess J. W., Jr, Kelliher J. C., Arthur L. O., Fischinger P. J. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol. 1988 Aug;62(8):2622–2628. doi: 10.1128/jvi.62.8.2622-2628.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Pau C. P., Lee-Thomas S., Auwanit W., George J. R., Ou C. Y., Parekh B. S., Granade T. C., Holloman D. L., Phillips S., Schochetman G. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS. 1993 Mar;7(3):337–340. doi: 10.1097/00002030-199303000-00005. [DOI] [PubMed] [Google Scholar]
  8. Potts K. E., Kalish M. L., Lott T., Orloff G., Luo C. C., Bernard M. A., Alves C. B., Badaro R., Suleiman J., Ferreira O. Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. Brazilian Collaborative AIDS Research Group. AIDS. 1993 Sep;7(9):1191–1197. doi: 10.1097/00002030-199309000-00007. [DOI] [PubMed] [Google Scholar]
  9. Redfield R. R., Wright D. C., Tramont E. C. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med. 1986 Jan 9;314(2):131–132. doi: 10.1056/NEJM198601093140232. [DOI] [PubMed] [Google Scholar]
  10. Warren R. Q., Anderson S. A., Nkya W. M., Shao J. F., Hendrix C. W., Melcher G. P., Redfield R. R., Kennedy R. C. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity. J Virol. 1992 Sep;66(9):5210–5215. doi: 10.1128/jvi.66.9.5210-5215.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Warren R. Q., Nkya W. M., Shao J. F., Anderson S. A., Wolf H., Hendrix C. W., Kanda P., Wabuke M., Boswell R. N., Redfield R. R. Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States. J Clin Microbiol. 1992 Jan;30(1):126–131. doi: 10.1128/jcm.30.1.126-131.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Warren R. Q., Wolf H., Shuler K. R., Eichberg J. W., Zajac R. A., Boswell R. N., Kanda P., Kennedy R. C. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. J Virol. 1990 Feb;64(2):486–492. doi: 10.1128/jvi.64.2.486-492.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wong M. T., Warren R. Q., Anderson S. A., Dolan M. J., Hendrix C. W., Blatt S. P., Melcher G. P., Boswell R. N., Kennedy R. C. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Infect Dis. 1993 Dec;168(6):1523–1527. doi: 10.1093/infdis/168.6.1523. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES